FemmePharma Global Healthcare
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, FemmePharma Global Healthcare sits in the upper quartile of US sponsors by registered trial count (#3,663 of 15,742 sponsors by registered trial count).
FemmePharma Global Healthcare: 3 sponsored US clinical trials, none currently recruiting.
FemmePharma Global Healthcare sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urinary Incontinence, Urge, with 1 trials.
Upper-quartile sponsor footprint
FemmePharma Global Healthcare sits in the upper quartile of the sponsor corpus (#3,663 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia
NCT01105793
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
NCT00749632
A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease
NCT00744276
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Therapeutic Areas
How the FemmePharma Global Healthcare early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Urinary Incontinence, Urge (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
FemmePharma Global Healthcare: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
FemmePharma Global Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this FemmePharma Global Healthcare page
3 registered trials is a research-attention snapshot, not an endorsement of FemmePharma Global Healthcare or any single study.
- None of FemmePharma Global Healthcare's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Urinary Incontinence, Urge is the condition FemmePharma Global Healthcare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urinary Incontinence, Urge trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. FemmePharma Global Healthcare pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.